JPMorgan Chase & Co. Sells 43,320 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

JPMorgan Chase & Co. decreased its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 365,921 shares of the company's stock after selling 43,320 shares during the period. JPMorgan Chase & Co. owned approximately 0.47% of Kura Oncology worth $3,187,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in KURA. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 14.6% in the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after buying an additional 615,211 shares during the last quarter. Wealthfront Advisers LLC purchased a new position in Kura Oncology in the fourth quarter worth $1,289,000. Barclays PLC increased its stake in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after acquiring an additional 84,563 shares during the last quarter. Jennison Associates LLC purchased a new stake in Kura Oncology during the fourth quarter valued at about $623,000. Finally, SG Americas Securities LLC bought a new stake in Kura Oncology during the fourth quarter worth about $436,000.

Insider Activity

In related news, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,729 shares of company stock valued at $92,307. Corporate insiders own 5.50% of the company's stock.

Analysts Set New Price Targets

KURA has been the topic of a number of research reports. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Scotiabank lowered their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. UBS Group reduced their target price on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 8th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $25.50.

Kura Oncology Trading Up 4.7 %

NASDAQ KURA opened at $6.18 on Tuesday. The stock has a market cap of $499.21 million, a P/E ratio of -2.62 and a beta of 0.83. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The stock has a 50 day simple moving average of $7.03 and a two-hundred day simple moving average of $10.26. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. On average, analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.